JP2018521993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521993A5 JP2018521993A5 JP2017566000A JP2017566000A JP2018521993A5 JP 2018521993 A5 JP2018521993 A5 JP 2018521993A5 JP 2017566000 A JP2017566000 A JP 2017566000A JP 2017566000 A JP2017566000 A JP 2017566000A JP 2018521993 A5 JP2018521993 A5 JP 2018521993A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- day
- effective amount
- therapeutically effective
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180914P | 2015-06-17 | 2015-06-17 | |
| US62/180,914 | 2015-06-17 | ||
| PCT/US2016/038110 WO2016205671A1 (en) | 2015-06-17 | 2016-06-17 | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182192A Division JP7036782B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182191A Division JP6675037B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521993A JP2018521993A (ja) | 2018-08-09 |
| JP2018521993A5 true JP2018521993A5 (https=) | 2019-07-04 |
| JP6599484B2 JP6599484B2 (ja) | 2019-10-30 |
Family
ID=57546446
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566000A Active JP6599484B2 (ja) | 2015-06-17 | 2016-06-17 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182191A Active JP6675037B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182192A Active JP7036782B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182191A Active JP6675037B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182192A Active JP7036782B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US10471087B2 (https=) |
| EP (3) | EP3310362B1 (https=) |
| JP (3) | JP6599484B2 (https=) |
| KR (3) | KR20180039624A (https=) |
| CN (2) | CN116726035A (https=) |
| AU (3) | AU2016280293B2 (https=) |
| BR (2) | BR112017027079B1 (https=) |
| CA (1) | CA2989653A1 (https=) |
| CY (2) | CY1122605T1 (https=) |
| DK (2) | DK3505174T3 (https=) |
| ES (2) | ES2748556T3 (https=) |
| HK (1) | HK1252133A1 (https=) |
| HR (2) | HRP20191794T1 (https=) |
| HU (2) | HUE046399T2 (https=) |
| IL (3) | IL275256B2 (https=) |
| LT (2) | LT3310362T (https=) |
| MX (2) | MX2017016425A (https=) |
| PL (2) | PL3505174T3 (https=) |
| PT (2) | PT3505174T (https=) |
| RS (2) | RS59724B1 (https=) |
| RU (1) | RU2721492C2 (https=) |
| SI (2) | SI3505174T1 (https=) |
| SM (2) | SMT202000399T1 (https=) |
| WO (1) | WO2016205671A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| US10292996B2 (en) | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| JP6599484B2 (ja) * | 2015-06-17 | 2019-10-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| PT4293009T (pt) | 2015-12-22 | 2025-09-08 | Zogenix International Ltd | Composições de fenfluramina e métodos de preparação das mesmas |
| AU2017315273B2 (en) | 2016-08-24 | 2021-04-29 | Zogenix International Limited | Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same |
| US11649442B2 (en) | 2017-09-08 | 2023-05-16 | The Regents Of The University Of California | RNA-guided endonuclease fusion polypeptides and methods of use thereof |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| US11628182B2 (en) * | 2018-04-12 | 2023-04-18 | Zogenix Mds, Inc. | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools |
| KR20210009317A (ko) | 2018-04-18 | 2021-01-26 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 미토콘드리아 dna 고갈 증후군을 포함하는 불균형 뉴클레오타이드 풀에 의해 초래된 질환에 대한 유전자 요법 |
| EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| AU2019384963B2 (en) | 2018-11-19 | 2022-05-26 | Zogenix International Limited | Methods of treating Rett syndrome using fenfluramine |
| CA3150755A1 (en) * | 2019-08-19 | 2021-02-25 | Modis Therapeutics, Inc. | Polymorphic forms of deoxycytidine, compositions comprising the same and uses |
| US20230000894A1 (en) * | 2019-09-05 | 2023-01-05 | Mitorainbow Therapeutics, Inc. | Treating mitochondrial dna depletion disorders |
| AU2021236683A1 (en) | 2020-03-19 | 2022-11-17 | Intellia Therapeutics, Inc. | Methods and compositions for directed genome editing |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20220096514A1 (en) * | 2020-09-29 | 2022-03-31 | Zogenix International Limited | Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine |
| EP4268829A4 (en) * | 2020-12-28 | 2024-11-27 | Yamasa Corporation | MUSCLE ATROPHY INHIBITOR AND METHOD FOR INHIBITING MUSCLE ATROPHY |
| EP4313068A4 (en) | 2021-03-26 | 2024-12-25 | UCB Biosciences, Inc. | Aqueous solutions containing purines and pyrimidines and uses thereof |
| US20230000890A1 (en) * | 2021-06-18 | 2023-01-05 | Zogenix Mds, Inc. | Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools |
| WO2024015453A1 (en) * | 2022-07-12 | 2024-01-18 | Zogenix Mds, Inc. | Methods for increasing the bioavailability of nucleoside medicinal agents |
| EP4687918A2 (en) * | 2023-03-30 | 2026-02-11 | The Trustees Of Columbia University In The City Of New York | Pharmacological therapy for mitochondrial dna depletion deletions syndrome involving mutations in the guk1 gene |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911237B (zh) * | 1998-08-10 | 2010-09-15 | 艾丹尼克斯(开曼)有限公司 | 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷 |
| IL144964A0 (en) * | 1999-02-23 | 2002-06-30 | Pro Neuron Inc | Methods of treatment of mitochondrial disorders |
| CN100490818C (zh) * | 2000-05-26 | 2009-05-27 | 诺瓦蒂斯有限公司 | β-L-2′-脱氧核苷在制备用于治疗丁型肝炎病毒感染的药物中的用途 |
| WO2012125848A2 (en) * | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| US10292996B2 (en) | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| BR112017025839A2 (en) * | 2015-06-05 | 2018-08-14 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | treatment of mitochondrial diseases |
| JP6599484B2 (ja) * | 2015-06-17 | 2019-10-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
-
2016
- 2016-06-17 JP JP2017566000A patent/JP6599484B2/ja active Active
- 2016-06-17 ES ES16812537T patent/ES2748556T3/es active Active
- 2016-06-17 CN CN202310757609.2A patent/CN116726035A/zh active Pending
- 2016-06-17 HK HK18111524.2A patent/HK1252133A1/zh unknown
- 2016-06-17 DK DK19156021.8T patent/DK3505174T3/da active
- 2016-06-17 RS RS20191295A patent/RS59724B1/sr unknown
- 2016-06-17 MX MX2017016425A patent/MX2017016425A/es active IP Right Grant
- 2016-06-17 US US15/736,092 patent/US10471087B2/en active Active
- 2016-06-17 RU RU2018101305A patent/RU2721492C2/ru active
- 2016-06-17 KR KR1020187001496A patent/KR20180039624A/ko not_active Ceased
- 2016-06-17 EP EP16812537.5A patent/EP3310362B1/en active Active
- 2016-06-17 MX MX2020000269A patent/MX389016B/es unknown
- 2016-06-17 SM SM20200399T patent/SMT202000399T1/it unknown
- 2016-06-17 HU HUE16812537A patent/HUE046399T2/hu unknown
- 2016-06-17 PT PT191560218T patent/PT3505174T/pt unknown
- 2016-06-17 HU HUE19156021A patent/HUE050678T2/hu unknown
- 2016-06-17 CA CA2989653A patent/CA2989653A1/en active Pending
- 2016-06-17 IL IL275256A patent/IL275256B2/en unknown
- 2016-06-17 BR BR112017027079-0A patent/BR112017027079B1/pt active IP Right Grant
- 2016-06-17 ES ES19156021T patent/ES2808148T3/es active Active
- 2016-06-17 PL PL19156021T patent/PL3505174T3/pl unknown
- 2016-06-17 CN CN201680045355.XA patent/CN107847512A/zh active Pending
- 2016-06-17 BR BR122020021913-0A patent/BR122020021913B1/pt active IP Right Grant
- 2016-06-17 SI SI201630830T patent/SI3505174T1/sl unknown
- 2016-06-17 SI SI201630439T patent/SI3310362T1/sl unknown
- 2016-06-17 PT PT168125375T patent/PT3310362T/pt unknown
- 2016-06-17 LT LT16812537T patent/LT3310362T/lt unknown
- 2016-06-17 RS RS20200779A patent/RS60572B1/sr unknown
- 2016-06-17 KR KR1020227002790A patent/KR20220018623A/ko not_active Ceased
- 2016-06-17 LT LTEP19156021.8T patent/LT3505174T/lt unknown
- 2016-06-17 KR KR1020257009842A patent/KR20250048602A/ko active Pending
- 2016-06-17 EP EP19178700.1A patent/EP3569236A1/en active Pending
- 2016-06-17 PL PL16812537T patent/PL3310362T3/pl unknown
- 2016-06-17 DK DK16812537.5T patent/DK3310362T3/da active
- 2016-06-17 AU AU2016280293A patent/AU2016280293B2/en active Active
- 2016-06-17 SM SM20190571T patent/SMT201900571T1/it unknown
- 2016-06-17 EP EP19156021.8A patent/EP3505174B1/en active Active
- 2016-06-17 WO PCT/US2016/038110 patent/WO2016205671A1/en not_active Ceased
- 2016-06-17 HR HRP20191794TT patent/HRP20191794T1/hr unknown
-
2017
- 2017-12-14 IL IL256331A patent/IL256331B/en active IP Right Grant
-
2019
- 2019-09-26 US US16/583,852 patent/US11110111B2/en active Active
- 2019-10-02 JP JP2019182191A patent/JP6675037B2/ja active Active
- 2019-10-02 JP JP2019182192A patent/JP7036782B2/ja active Active
- 2019-10-30 CY CY20191101127T patent/CY1122605T1/el unknown
-
2020
- 2020-06-09 IL IL275255A patent/IL275255B/en active IP Right Grant
- 2020-06-15 HR HRP20200949TT patent/HRP20200949T1/hr unknown
- 2020-06-17 AU AU2020204042A patent/AU2020204042B2/en active Active
- 2020-06-25 CY CY20201100578T patent/CY1123107T1/el unknown
-
2021
- 2021-04-28 US US17/242,822 patent/US11666592B2/en active Active
- 2021-10-11 AU AU2021250841A patent/AU2021250841B2/en active Active
-
2023
- 2023-04-24 US US18/138,432 patent/US12251392B2/en active Active
-
2025
- 2025-02-11 US US19/050,489 patent/US20250360154A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521993A5 (https=) | ||
| HRP20200949T1 (hr) | Deoksinukleozidna terapija bolesti uzrokovanih neurevnoteženim fondovima nukleotida, uključujući sindrome manjka mitohondrijske dna | |
| KR101676062B1 (ko) | Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제 | |
| JP2016533379A5 (https=) | ||
| ES2797900T3 (es) | Compuestos y combinaciones para el tratamiento del VIH | |
| Asselah | Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy | |
| RU2017142555A (ru) | Способ стимуляции кишечной флоры | |
| JP2014077003A5 (https=) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2015078220A5 (https=) | ||
| RU2018139655A (ru) | Бифидобактерии для увеличения безжировой массы тела | |
| Sey et al. | The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections | |
| JP2016539156A5 (https=) | ||
| JP2017531673A5 (https=) | ||
| JP2019038796A5 (https=) | ||
| NO20073813L (no) | Kladribinregime for behandling av multippel sklerose | |
| JP2021073257A5 (https=) | ||
| JP2019038797A5 (https=) | ||
| JP2009517391A5 (ja) | 胃腸障害の処置のための医薬組成物 | |
| JP2019504860A5 (https=) | ||
| CN1615136A (zh) | 包含埃坡霉素和抗代谢物的组合 | |
| JP2016014051A5 (https=) | ||
| CA3037779A1 (en) | Treatment of inflammatory bowel disease with nucleoside triphosphate disphoshohydrolase, p2y2 antagonist and/or p2y6 antagonist | |
| EP3600332A1 (en) | Hiv post-exposure prophylaxis | |
| Karthik | Yoghurt (LAB) as preventive method against COVID-19 |